Guys, how do you invent a vaccine? Or wilder, how do you invent a vaccine during your PhD?!
In a new episode of Hard Drugs, we talked to someone who did just that:
@Kat_a_Collins!
A single malaria parasite that reaches your liver is enough to cause an infection. Worse, malaria has a complicated lifecycle with multiple stages, during which it changes shape and switches its surface proteins. And it’s co-evolved with humans for thousands of years, learning to evade and misdirect our immune system.
That’s why it’s been so much harder to develop vaccines against than viruses or bacteria. But not impossible!
In this episode,
@JacobTref and I are joined by Katharine Collins, who co-invented the second malaria vaccine, R21, during her PhD at the Jenner Institute in Oxford!
After reading the expired patent of the first malaria vaccine (RTS,S), she stripped out the excess Hepatitis B surface antigen that RTS,S, leaving a particle with a much higher proportion of malaria antigen, used many newer processes, and paired it with a cheaper, more scalable adjuvant.
The result is a vaccine that’s around a third of the price, easier to manufacture at scale, and may be more durable as well.
It also means a vaccine that can reach far more children and save far more lives. Efficiency and scale matter enormously in the real world.
It’s probably our coolest episode ever. You will learn lots of secret, behind the scenes information about how innovation really works.
We chat about all this and much more!
Timestamps:
00:00 Introduction
05:08 Our favourite parasites
10:12 How to invent a vaccine during your PhD
34:18 Why is it called the R21 vaccine?
37:32 Moving from the bench to hundreds of millions of doses
41:43 The vicious life cycle of malaria parasites
46:15 Malaria research IN MICE
53:03 The murderer in malaria research
55:51 Would you volunteer to get infected by malaria?
1:08:21 Why did the first malaria vaccine take so long?
1:18:26 Could we have had the vaccine sooner?
1:40:48 Vaccine versus vaccine: which one’s better?
1:46:53 If we did this again today, could we make better vaccines?
2:04:55 Conclusion and our reasons for pessimism and optimism